Alzheimer's disease (AD) is the most common cause of dementia in adulthood, followed by cognitive and behavioral deficits. Today, mesenchymal stem cell (MSC)-based therapy is a suitable therapeutic option to improve regenerative medicine approaches against neurodegenerative disorders, including AD. This study aimed to investigate the effects of human Wharton’s jelly-derived MSCs (WJ-MSCs) on AD-like rat models (rats treated with amyloid beta 1-42 (Aβ1-42)) by evaluating the expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), as well as the expression of apoptotic factors such as B-cell lymphoma 2 (BCL2, an anti-apoptotic factor to inhibit apoptosis) and BCL2-associated X protein (BAX, a pro-apoptotic factor to regulate apoptosis). After treatment of AD rat models with WJ-MSCs, behavioral tests (i.e., passive avoidance and Morris water …

Mehdi Mehdizadeh, Ph.D, is a specialist in Anatomical Sciences and a Fellow in Transgenic Animals at the Reproductive science and technology research center, Iran University of Medical Sciences, Tehran, Iran. His research focuses on regenerative medicine, reproductive biology, and nanotechnology-based drug delivery systems. He has contributed to multiple peer-reviewed publications and international conferences. His work aims to develop novel therapeutic strategies for treating infertility and tissue regeneration disorders.